Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  van Zuuren, Esther J ^a   Fedorowicz, Zbys ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Bahrain Branch   (Bahrain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN; OPIATE; TINZAPARIN;

BLEEDING; BLOOD VESSEL OCCLUSION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL PROTOCOL; DISEASE DURATION; DRUG EFFECT; HUMAN; LENGTH OF STAY; PAIN; PAIN ASSESSMENT; PAIN SEVERITY; PATIENT CARE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SENSITIVITY ANALYSIS; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; COMPLICATION; PERIPHERAL VASCULAR DISEASES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANEMIA, SICKLE CELL; ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PERIPHERAL VASCULAR DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84891690731     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010155.pub2     Document Type: Review

References (40)

1. Qari MH, Aljaouni SK, Alardawi MS, Fatani H, Alsayes FM, Zografos P, et al.Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thrombosis and Haemostasis 2007;98(2):392-6. [PUBMED: PMID: 17721622]
2. Qari MH, Mousa S, Alsaigh MA, Zografos P, Aljaouni SK, Fatani H, et al.Tinzaparin in the management of painful vaso-occlusive crisis of sickle cell anaemia. Blood 2005;106(11):Abstract no: 2340.
3. NCT01419977. Treatment of sickle cell patients hospitalized in pain crisis with prophylactic dose low-molecular-weight heparin (LMWH) versus placebo. www.clinicaltrials.gov/show/NCT01419977 (accessed 01 March 2013).
4. Al Hajeri A, Serjeant GR, Fedorowicz Z. Inhaled nitric oxide for acute chest syndrome in people with sickle cell disease. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD006957]
5. Ataga KI, Brittain JE, Desai P, May R, Jones S, Delaney J, et al.Association of coagulation activation with clinical complications in sickle cell disease. Plos One 2012;7(1):e29786. [PUBMED: PMID: 22253781]
6. Austin H, Key NS, Benson JM, Lally C, Dowling NF, Whitsett C, et al.Sickle cell trait and the risk of venous thromboembolism among blacks. Blood 2007;110(3):908-12. [PUBMED: PMID: 17409269]
7. Austin H, Lally C, Benson JM, Whitsett C, Hooper WC, Key NS. Hormonal contraception, sickle cell trait, and risk for venous thromboembolism among African American women. American Journal of Obstetrics and Gynecology 2009;200(6):620.e1-3. [PUBMED: PMID: 19306959]
8. Ballas SK, Lieff S, Benjamin LJ, Dampier CD, Heeney MM, Hoppe C, et al.Definitions of the phenotypic manifestations of sickle cell disease. American Journal of Hematology 2010;85(1):6-13. [PUBMED: PMID:19902523]
9. Ballas SK, Kesen MG, Goldberg MF, Lutty GA, Dampier C, Osunkwo I, et al.Beyond the definitions of the phenotypic complications of sickle cell disease: An update on management. The Scientific World Journal 2012;2012:949535. [DOI: 10.1100/2012/949535]
10. Ballas SK. Sickle cell anemia. http://pier.acponline.org/physicians/diseases/d905/d905.html (accessed 28 February 2013):1-93.
11. Brown P, Brunnhuber K, Chalkidou K, Chalmers I, Clarke M, Fenton M, et al.How to formulate research recommendations. BMJ 2006;333(7572):804-6.
12. Bunn HF, Nathan DG, Dover GJ, Hebbel RP, Platt OS, Rosse WF, et al.Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood 2010;116(5):687-92. [PUBMED: PMID:20395414]
13. Carr JA, Cho JS. Low molecular weight heparin suppresses tumor necrosis factor expression from deep vein thrombosis. Annals of Vascular Surgery 2007;21(1):50-5. [PUBMED: PMID: 17349336]
14. Davies EG, Hirst C, Lottenberg R, Dower N. Pneumococcal vaccines for sickle cell disease. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD003885.pub2]
15. De Franceschi L. Pathophisiology of sickle cell disease and new drugs for the treatment. Mediterranean Journal of Hematology and Infectious Diseases 2009;1(1):e2009024. [PUBMED: PMID:21415994]
16. De Franceschi L, Cappellini MD, Olivieri O. Thrombosis and sickle cell disease. Seminars in Thrombosis and Hemostasis 2011;37(3):226-36. [PUBMED: PMID: 21455857]
17. de Montalembert M. Management of sickle cell disease. BMJ 2008;337:a1397. [PUBMED: PMID: 18779222]
18. Gladwin MT, Sachdev V. Cardiovascular abnormalities in sickle cell disease. Journal of the American College of Cardiology 2012;59(13):1123-33. [PUBMED: PMID:22440212]
19. Goldsmith JC, Bonham VL, Joiner CH, Kato GJ, Noonan AS, Steinberg MH. Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications. American Journal of Hematology 2012;87(3):340-6. [PUBMED: PMID: 22307997]
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
21. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
22. Sterne JAC, Egger M, Moher D, on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
23. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org .
24. Higgins JPT, Deeks JJ, Altman DG on behalf of the CSMG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
25. Hirani A, Weibel S, Kane GC. Acute chest syndrome and other pulmonary manifestations of sickle cell disease. Journal of Clinical Outcome Management 2011;18(5):211-21.
26. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992;79(1):1-17. [PUBMED: PMID: 1309422]
27. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al.Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119 Suppl 1:64S-94S. [PUBMED: PMID: 11157643]
28. Hoy SM, Scott LJ, Plosker GL. Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis. Drugs 2010;70(10):1319-47. [PUBMED: PMID: 20568836]
29. Inati A. Recent advances in improving the management of sickle cell disease. Blood Reviews 2009;23 Suppl 1:S9-13. [PUBMED: PMID: 20116638]
30. Inati A, Chabtini L, Mounayar M, Taher A. Current understanding in the management of sickle cell disease. Hemoglobin 2009;33 Suppl 1:S107-15. [PUBMED: PMID: 20001613]
31. Jaywant S, Pai A. A comparative study of pain measurement scales in acute burn patients. Indian Journal of Occupational Therapy 2003;35(3):13-7.
32. Key NS, Derebail VK. Sickle-cell trait: novel clinical significance. Hematology/ the Education Program of the American Society of Hematology 2010;2010:418-22. [PUBMED: PMID: 21239829]
33. Mousa SA, Bozarth J, Barrett JS. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. Journal of Clinical Pharmacology 2003;43(7):727-34. [PUBMED: PMID: 12856386]
34. Mousa SA, Al Momen A, Al Sayegh F, Al Jaouni S, Nasrullah Z, Al Saeed H, et al.Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clinical and Applied Thrombosis/Haemostasis 2010;16(4):365-76. [PUBMED: PMID: 20530056]
35. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010;376(9757):2018-31. [PUBMED: PMID: 21131035]
36. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
37. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
38. Steinberg MH. Management of sickle cell disease. New England Journal of Medicine 1999;340(13):1021-30. [PUBMED: PMID: 10099145]
39. Steinberg MH. In the Clinic. Sickle cell disease. Annals of Internal Medicine 2011;155(5):ITC31-15. [PUBMED: 21893620]
40. World Health Organization. Sickle-cell anaemia. Report A59/9. Provisional agenda item 11.4. 59th World Health Assembly. https://apps.who.int/gb/ebwha/pdf_files/WHA59/A59_9-en.pdf (accessed 13 March 2012).